macdougall musings

JP Morgan Healthcare Conference Poised to Set the Tone for 2023

by Sara Michelmore, Managing Director, Investor Relations

As we enter the final stretch of 2022, many across the industry are eager to close the book on a year that brought multiple macro headwinds, volatile market performance, negative investor sentiment and increased economic uncertainties.

Looking ahead, it is notable that the annual JP Morgan Healthcare Conference (“JPM”) is returning to its in-person format this January and is expected once again to draw key stakeholders from across the industry including the investment community, C-suite executives and business development teams. News flow, sentiment and activity out of this year’s meeting appears very much poised to set the tone and define expectations for 2023.

Key areas we will be keeping an eye on are the following:

  • “Big” news, particularly M&A. Historically, JPM has been a meeting where notable M&A transactions are announced. While M&A activity picked up in certain sectors in 2022, including biotech, overall deal size has been underwhelming. One or more sizeable transaction announcements could catalyze excitement around the potential for significant consolidation in certain sub-sectors during 2023.
  • Confidence around financial outlooks & guidance. Visibility on financial outlooks has been challenging for corporates over the last year, reflecting a more uncertain environment and increased risk to earnings expectations. Higher confidence in the outlooks communicated by executive teams and increased comfort around earnings expectations by investors would be a constructive development coming out of JPM.
  • Upcoming flow of news catalysts, particularly in innovation-driven sectors like biotech. With many emerging growth companies adjusting strategies to focus on their highest priority value drivers in 2022, JPM is an opportunity for investors to newly assess the multitude of catalyst-driven opportunities for the year ahead. We will be looking for companies, particularly in biotech, to utilize JPM to level set expectations around timing of key milestones for the next 12-24 months.
  • Investor sentiment, including appetite for capital deployment. 2022 saw a significant drop off in the number and volume of private and public transactions as investors exercised more caution and exhibited higher risk aversion. Exiting the meeting, there is likely to be a consensus view regarding investor sentiment overall and their willingness to deploy capital, and “where” and “how” it is likely to be preferentially deployed. Providing this context enables investors to understand how you, as managers, make capital allocation decisions and provides a helpful framework from which they can evaluate your progress. Even when resources feel constrained, companies should not neglect the work of building a durable balance sheet that supports long-term enterprise value creation. This includes building asset portfolios inclusive of intellectual property, facilities and other assets.
After a two-year hiatus, our team is looking forward to returning to JPM in person and sharing our reflections and insights with our clients and colleagues.
Looking for counsel on how to make the most out of JPM 2023 or how to effectively communicate your equity story for the coming year? Contact our Head of Investor Relations, Sara Michelmore, to learn more.

Creative Services

Digital Media
& Content

More than a Tweet
Building your brand and voice is a key function of digital media, but, with the right goals in mind, digital media can be much more. Meet your audiences where they are by building digital campaigns and content that help to connect and engage your stakeholders.
  • Social media strategy & content
  • Narrative building
  • Blog creation and execution
  • Metrics, monitoring and reporting
  • Social listening
  • Executive digital profile strategy and management
  • Influencer monitoring and engagement
  • Digital advertising
  • Content creation, design and marketing
  • Video creation and podcasting

Investor
Relations

Credibility is your most important asset
Investor relations is about building trust, transparency and liquidity. The MacDougall IR team has helped many clients bridge from private to public and showcase our public clients to new investors and analysts.
  • Audience targeting
  • Shareholder communication
  • IPO preparations and communications
  • Conference calls & webcasts
  • Conference outreach and support
  • Presentations
  • Special events
  • R&D days
  • Perception audits

Digital
& Creative

A picture is worth a thousand words
Visual first impressions are so important in this era of precipitous information. Our digital and creative services team are true life science artists devoted to visual storytelling and capturing eyeballs.
  • Branding & identity​
  • Visual storytelling​
  • Logo design​
  • Website design & development​
  • Scientific illustration & MOA graphics​
  • Infographics / data visualization​
  • Animation & video production​
  • Presentation design​
  • Scientific posters​
  • HTML emails & newsletters
  • Advertisements

Thought
Leadership

Be known for making a difference
Thought leadership campaigns open many channels to promote both a personal brand as well as your organization. Let’s pick a subject and run with it together.
  • Executive profile building​
  • Strategic counsel
  • Presentation coaching​
  • Speech writing​
  • Media training​
  • Social media​

Scientific & Medical Communications

Show and tell

From preclinical to platform to Phase 3 results, strategic medical and scientific communications is the cornerstone to building visibility and credibility with your target audiences.

  • Medical and scientific meeting support
  • Patient recruitment for clinical trials
  • Disease awareness campaigns
  • Patient advocacy outreach
  • Data communications
  • KOL identification and development
  • Custom scientific symposia/events​

Public
Relations

We love telling stories
Public relations is about building your network and getting other people talking about you. We want to help you build buzz and credibility at the same time.
  • Company debuts​
  • Media campaigns ​
  • Social media strategy & content​
  • Press releases writing, editing & pitching​
  • Ongoing trend story development & pitching​
  • Conference tracking & management​
  • Disease awareness campaigns
  • Clinical trial recruitment campaigns
  • Media monitoring & analytics
  • Events​

Business
Advisory

Think before you talk
We have seen it all. Helping our clients navigate the macro and micro ups and downs of the life science and healthcare industry is our passion.
  • Corporate branding, positioning and message development
  • Product and technology branding
  • Public policy advisory
  • Crisis communications
  • Strategic communications plans
  • Capital markets advisory
  • Scientific and medical publication and presentation strategies
  • Board presentations
  • Competitive intelligence
  • M&A advisory & rebranding
  • Corporate rebranding